3 of the Worst Performing IPOs You Wish You Didn't Buy in 2014

Not all IPOs live up to their hype. In fact, some IPOs pop right out of the gate because of just that: hype. TheStreet analyzed how much retail investors would have lost if they had invested in some of the worst performing IPOs of the year, with the help of data provided by Dealogic. First up, Amedica Corp. (AMDA), which went public just over a year ago: shares are down 90% since its first trading day high of $6.50. Up next, Biocept (BIOC), which also debuted on the Nasdaq last February, but shares slipped 82% since then. Its inaugural trading day high was $10.02 per share, and as of February 5th, trades at $1.76. Finally, molecular diagnostic company Signal Genetics (SGNL) went public last June. Shares have since fallen 80%, as the $8.5 million IPO is now trading around $2 per share. A far cry from it's opening day high of just under $10-dollars. TheStreet's Scott Gamm has details from New York.

undefined